法国赛诺菲的喜保宁哪里有卖？

(Vigabatrin), approved for marketing in the UK in 1989 and approved by the US Food and Drug Administration in 2009 for the treatment of infantile spasms and refractory focal epilepsy, making it one of the first-choice drugs for the treatment of infantile spasms, especially in patients with tuberous sclerosis. Vigabatrin is a structural analog of gamma-aminobutyric acid (GABA). It inhibits the catabolism of GABA by irreversibly inhibiting GABA transaminase, thereby increasing the concentration of GABA in the brain and achieving anti-epileptic therapeutic effects.

Vigabatrin was developed by the French company Sanofi. The French Sanofi Group is the number one pharmaceutical company in Europe and the third largest pharmaceutical company in the world. It was established in 2004 by the merger of Sanofi Sandra Fort Group and Aventis Pharmaceuticals. Headquartered in Paris, it has branches in more than 80 countries and employs more than 100,000 people.

Where can I buy Vigabatrin from Sanofi in France? According to Medical Travel, France's Sanofi's Vigabatrin has not yet been approved for marketing in China. It is neither produced by a manufacturer nor sold by merchants. Patients cannot buy the drug in China. Many patients can only find someone to buy them on their behalf and are deceived by buying fake and inferior drugs. If a patient friend needs French Sanofi listed overseas, he can go abroad to buy it in person, or he can contact a legal and formal overseas medical service company in China to obtain it.

Recommended related hot articles: /newsDetail/95625.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.